Carmelle Romain1, Pritha Paul2, Kwang Woon Kim1, Sora Lee2, Jingbo Qiao1, Dai H Chung3. 1. Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville TN. 2. Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville TN; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville TN. 3. Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville TN; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville TN. Electronic address: dai.chung@vanderbilt.edu.
Abstract
PURPOSE: Aurora kinase A (AURKA) overexpression is associated with poor prognosis in neuroblastoma and has been described to upregulate VEGF in gastric cancer cells. However, the exact role of AURKA in the regulation of neuroblastoma tumorigenesis remains unknown. We hypothesize that AURKA-mediated stabilization of N-Myc may affect VEGF expression and angiogenesis in neuroblastoma. Therefore, we sought to determine whether inhibition of AURKA modulates neuroblastoma angiogenesis. METHODS: Cell viability and anchorage-independent growth were determined after silencing AURKA or after treatment with MLN8237, AURKA inhibitor. Immunofluorescence was used to determine N-Myc localization. Human umbilical vein endothelial cells (HUVECs) were used to assess angiogenesis in vitro. Real time-PCR and ELISA were performed to determine VEGF transcription and secretion, respectively. RESULTS: Knockdown of AURKA significantly reduced cell proliferation and inhibited anchorage-independent growth. It also decreased N-Myc protein levels and nuclear localization. AURKA inhibition also decreased HUVECs tubule formation along with VEGF transcription and secretion. Similarly, MLN8237 treatment decreased neuroblastoma tumorigenicity in vitro. CONCLUSIONS: Our findings demonstrate that AURKA plays a critical role in neuroblastoma angiogenesis. AURKA regulates nuclear translocation of N-Myc in neuroblastoma cells, thus potentially affecting cell proliferation, anchorage-independent cell growth, and angiogenesis. Targeting AURKA might provide a novel therapeutic strategy in treating aggressive neuroblastomas.
PURPOSE:Aurora kinase A (AURKA) overexpression is associated with poor prognosis in neuroblastoma and has been described to upregulate VEGF in gastric cancer cells. However, the exact role of AURKA in the regulation of neuroblastoma tumorigenesis remains unknown. We hypothesize that AURKA-mediated stabilization of N-Myc may affect VEGF expression and angiogenesis in neuroblastoma. Therefore, we sought to determine whether inhibition of AURKA modulates neuroblastoma angiogenesis. METHODS: Cell viability and anchorage-independent growth were determined after silencing AURKA or after treatment with MLN8237, AURKA inhibitor. Immunofluorescence was used to determine N-Myc localization. Human umbilical vein endothelial cells (HUVECs) were used to assess angiogenesis in vitro. Real time-PCR and ELISA were performed to determine VEGF transcription and secretion, respectively. RESULTS: Knockdown of AURKA significantly reduced cell proliferation and inhibited anchorage-independent growth. It also decreased N-Myc protein levels and nuclear localization. AURKA inhibition also decreased HUVECs tubule formation along with VEGF transcription and secretion. Similarly, MLN8237 treatment decreased neuroblastoma tumorigenicity in vitro. CONCLUSIONS: Our findings demonstrate that AURKA plays a critical role in neuroblastoma angiogenesis. AURKA regulates nuclear translocation of N-Myc in neuroblastoma cells, thus potentially affecting cell proliferation, anchorage-independent cell growth, and angiogenesis. Targeting AURKA might provide a novel therapeutic strategy in treating aggressive neuroblastomas.
Authors: Jeanette D Walton; David R Kattan; Sharon K Thomas; Barbara A Spengler; Hong-Fen Guo; June L Biedler; Nai-Kong V Cheung; Robert A Ross Journal: Neoplasia Date: 2004 Nov-Dec Impact factor: 5.715
Authors: A Kallioniemi; O P Kallioniemi; J Piper; M Tanner; T Stokke; L Chen; H S Smith; D Pinkel; J W Gray; F M Waldman Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205
Authors: Yael P Mossé; Elizabeth Fox; David T Teachey; Joel M Reid; Stephanie L Safgren; Hernan Carol; Richard B Lock; Peter J Houghton; Malcolm A Smith; David Hall; Donald A Barkauskas; Mark Krailo; Stephan D Voss; Stacey L Berg; Susan M Blaney; Brenda J Weigel Journal: Clin Cancer Res Date: 2019-02-18 Impact factor: 12.531
Authors: Konstantinos Zormpas-Petridis; Neil P Jerome; Matthew D Blackledge; Fernando Carceller; Evon Poon; Matthew Clarke; Ciara M McErlean; Giuseppe Barone; Alexander Koers; Sucheta J Vaidya; Lynley V Marshall; Andrew D J Pearson; Lucas Moreno; John Anderson; Neil Sebire; Kieran McHugh; Dow-Mu Koh; Yinyin Yuan; Louis Chesler; Simon P Robinson; Yann Jamin Journal: Cancer Res Date: 2019-03-15 Impact factor: 12.701